{"filings":[{"id":1194799,"accession_number":"0001628280-26-044618","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-06-22T20:05:46+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Allogene shareholders approve doubling authorized shares to 800M; files $135M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase of authorized common shares from 400M to 800M, effective June 18, 2026.","Advisory 'say-on-pay' vote approved; board adopts annual frequency for future advisory votes.","Company filed prospectus supplement for up to $135M in common stock sales via ATM with TD Securities.","All three Class II director nominees (Messemer, Sato, Witte) re-elected with strong support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":724077,"accession_number":"0001193125-26-245484","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-05-28T21:06:28+00:00","items":["5.02"],"status":"ready","headline":"Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.","Dr. Roberts receives $680k base salary, 60% target bonus, options for 476,190 shares, and 134,530 RSUs.","Outgoing CEO David Chang, M.D., Ph.D. will remain on the Board as a non-employee director after June 30, 2026.","Dr. Chang eligible for severance benefits under Allogene's Change in Control and Severance Benefit Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67881,"accession_number":"0001628280-26-034583","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-05-13T20:03:30+00:00","items":["1.01","1.02","2.02","9.01"],"status":"ready","headline":"Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Terminated exclusive license with Overland; retains ~3% equity; no termination payments.","ALPHA3 interim: 58.3% MRD clearance in cema-cel arm vs 16.7% observation; no CRS/ICANS/GvHD.","Q1 net loss $42.6M ($0.18/sh); operating cash expense guidance raised to ~$165M.","Cash $266.9M; April public offering grossed $200.4M; runway into Q1 2029.","ALLO-329 Phase 1 RESOLUTION dosed 9 patients; initial signs of activity; next update Q4 2026."],"consensus_eps_estimate":-0.1942,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95088,"accession_number":"0001193125-26-157140","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allogene prices $175M public offering of 87.5M shares at $2.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.","Underwriters granted 30-day option to buy up to 13,125,000 additional shares at same price.","Closing expected on or about April 16, 2026, subject to customary conditions.","Net proceeds for general corporate purposes including clinical trials and R&D.","Goldman Sachs, Jefferies, and TD Cowen act as joint bookrunners; Piper Sandler and William Blair also joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95087,"accession_number":"0001193125-26-152866","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene Therapeutics launches underwritten public offering, suspends ATM sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company announced proposed underwritten public offering of common stock on April 13, 2026.","Sales under existing ATM agreement with TD Securities are suspended pending new prospectus.","No offering size or pricing details disclosed in the 8-K; further supplement expected.","Proceeds intended for general corporate purposes; dilution to existing shareholders anticipated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95086,"accession_number":"0001193125-26-151999","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.","No CRS, ICANS, or GvHD reported; 10 of 12 cema-cel patients managed fully outpatient.","Plasma ctDNA decreased 97.7% median in cema-cel arm vs 26.6% increase in observation at Day 45.","Cema-cel arm had more aggressive disease (100% stage III-IV, 41.7% IPI 4-5) than observation.","ALPHA3 targets ~220 patients; enrollment complete by end 2027; interim EFS mid-2027, primary mid-2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107903,"accession_number":"0001628280-26-017230","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).","Cash, equivalents, investments $258.3M; runway extended into Q1 2028 via disciplined spending, $23.7M escrow return.","Pivotal Phase 2 ALPHA3 trial of cema-cel in 1L LBCL; interim futility analysis (MRD clearance, safety) planned April 2026.","Phase 1 RESOLUTION trial of ALLO-329 (CD19/CD70 CAR T) in autoimmune diseases; proof-of-concept data expected June 2026.","ALLO-316 TRAVERSE trial in RCC completed Phase 1b enrollment; exploring partnering opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124316,"accession_number":"0001628280-25-050227","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.","Phase 2 ALPHA3 trial for cema-cel in LBCL on track for futility analysis in 1H 2026.","Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease enrolling, proof-of-concept data expected 1H 2026.","Phase 1 TRAVERSE trial for ALLO-316 in RCC shows durable responses; next phase under evaluation.","Additional ALPHA3 trial sites in Australia and South Korea expected to open early 2026."],"consensus_eps_estimate":-0.2277,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124315,"accession_number":"0001628280-25-044828","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.","Allogene relies on Cellectis's TALEN technology for allogeneic CAR T candidates including cema-cel and ALLO-316.","Cellectis notified Allogene on October 6, 2025, and intends to vigorously defend against the claims.","Factor may also assert direct claims against Allogene as a commercial user of the disputed technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140991,"accession_number":"0001737287-25-000087","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.","Pivotal ALPHA3 trial for cema-cel in LBCL proceeding as randomized two-arm study; futility analysis on track for 1H 2026.","Phase 1 RESOLUTION trial with ALLO-329 initiated in rheumatology autoimmune diseases; proof-of-concept data expected 1H 2026.","ALLO-316 completed Phase 1b enrollment in RCC; FDA aligned on pivotal trial design, partnership discussions possible.","Cash runway projected into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP OpEx ~$230M."],"consensus_eps_estimate":-0.279,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140990,"accession_number":"0001193125-25-171091","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.","ALLO-647 removed from all ongoing and pipeline programs; no trial includes it.","ALPHA3 proceeds as randomized trial of cema-cel with standard FC vs observation.","Futility analysis on MRD conversion expected in first half 2026.","Over 50 clinical sites activated; next-gen AlloCAR T uses Dagger Platform to reduce lymphodepletion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158760,"accession_number":"0001737287-25-000070","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allogene shareholders elect three Class I directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elizabeth Barrett, Arie Belldegrun, and David Chang elected as Class I directors with >131M votes for each.","Advisory vote on NEO compensation approved: 139.9M for, 14.2M against, 3.2M abstain.","Ratification of Ernst & Young as auditor for FY2025: 190.1M for, 414.6K against.","All proposals passed with no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158759,"accession_number":"0001737287-25-000063","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.","ALPHA3 (cema-cel) lymphodepletion/futility analysis shifted to 1H 2026; >250 patients consented, ~50 sites activated.","ALLO-329 RESOLUTION basket trial in AID starts mid-2025; proof-of-concept data moved to 1H 2026.","ALLO-316 TRAVERSE updated Phase 1b results to be presented at ASCO June 1, 2025.","Cash runway extended into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP op ex ~$230M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177163,"accession_number":"0001737287-25-000035","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.","Cash & investments $373.1M; cash runway into 2H 2026; 2025 guidance: ~$170M cash burn.","ALPHA3 pivotal trial for cema-cel in 1L LBCL: 40 sites activated; futility analysis mid-2025; primary EFS data YE2026.","ALLO-329 autoimmune: IND cleared; RESOLUTION basket trial start mid-2025; proof-of-concept data YE2025.","ALLO-316 RCC: Phase 1b expansion fully enrolled; data mid-2025; RMAT designation received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177162,"accession_number":"0001193125-25-035162","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.","Allogene to fund approximately $37.3 million for assay development, milestone payments, and clinical sample testing.","Parties will use commercially reasonable efforts to obtain regulatory approval for respective products.","Each party retains ownership of its background IP and improvements; termination rights unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177161,"accession_number":"0001193125-25-014985","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene Therapeutics officer Timothy Moore to depart Feb 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Moore leaving employment on February 28, 2025; departure treated as termination without cause.","Eligible for cash severance and COBRA reimbursement under the company's Change in Control and Severance Benefit Plan, subject to release.","Company intends to enter into a consulting agreement with Moore, terms to be mutually agreed.","No immediate replacement for Moore has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193943,"accession_number":"0001737287-24-000075","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.","Enrollment slower than anticipated due to emergence of new alternative treatment options.","Interest among investigators remains high but company is reallocating resources to other pipeline programs.","No financial impact or guidance changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193942,"accession_number":"0001737287-24-000072","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.","Ended Q3 with $403.4M cash; maintains 2024 cash burn ~$200M and runway into 2H 2026.","Pivotal ALPHA3 cema-cel trial in 1L LBCL: ~30 sites active; enrollment completion expected 1H 2026; BLA submission targeted 2027.","ALLO-329 (CD19/CD70 dual CAR) for autoimmune disease: IND planned Q1 2025, proof-of-concept by YE 2025.","ALLO-316 for RCC received RMAT designation; Phase 1 TRAVERSE showed 50% ORR in CD70 TPS ≥50% patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":22000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193941,"accession_number":"0001737287-24-000062","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.05","9.01"],"status":"ready","headline":"Allogene Therapeutics amends Code of Business Conduct and Ethics","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updates insider trading policy, antitrust restrictions, and conflicts-of-interest procedures.","Expands fair dealing obligations, gift/entertainment restrictions, and data privacy/cybersecurity requirements.","Adds express requirement to comply with all other Company policies supporting the Code.","Applies to all directors, officers, employees, and certain consultants/contractors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210265,"accession_number":"0001737287-24-000055","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.","Cash, equivalents and investments $444.6M as of June 30, 2024; runway into 2H 2026.","Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL initiated; enrollment completion expected 1H 2026, BLA submission 2027.","ALLO-329 (CD19/CD70 dual CAR) IND on track for Q1 2025 in autoimmune disease; proof-of-concept by YE 2025.","ALLO-316 Phase 1 TRAVERSE data update with ~20 RCC patients planned for YE 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":22000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228566,"accession_number":"0001737287-24-000050","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.","Yoshiyama previously VP Finance & Controller at AN2 Therapeutics and CAO at Tricida.","Shareholders elected four Class III directors (DeYoung, Humer, Kazam, Mayo) to serve until 2027.","Advisory say-on-pay approved with 119.7M votes for, 16.3M against.","Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228565,"accession_number":"0001737287-24-000046","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).","Overland's ownership in JV increases to 69.63%; Allogene's drops to 15.37% after share incentive plan increase.","Exclusive license royalty changed to flat mid single-digit on net sales in territory, no longer subject to reductions.","Allogene gains termination rights for funding default or failure to initiate tech transfer; license auto-terminates if Allogene's ownership <7.5% unless mutual plan agreed.","Overland distributes all JV shares to HH BioPharma Holdings (HBP), which gets 3 of 5 board seats."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228564,"accession_number":"0001193125-24-138316","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allogene Therapeutics raises $110M in registered equity offering at $2.90 per share with insider participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 37,931,035 shares at $2.90 per share for gross proceeds of ~$110M; expected to close May 16, 2024.","Insiders Arie Belldegrun, David Chang, and Geoffrey Parker each purchasing 344,828 shares in the offering.","Goldman Sachs & Co. LLC acted as sole underwriter; offering made under effective shelf registration statement.","Net proceeds after underwriting discounts and expenses will be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228563,"accession_number":"0001737287-24-000040","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene expands CD19 rights to EU/UK; Q1 net loss $65M; cash $397M into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expanded CD19 oncology rights to all EU Member States and UK from Servier; combined market opportunity increased to >$9.5B from $6B.","Q1 2024 net loss of $65.0M ($0.38 per share); R&D expenses $52.3M, G&A $17.3M.","Cash, cash equivalents, and investments $397.3M as of March 31, 2024; cash runway expected into 2026.","Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL to start mid-2024; primary EFS data readout expected 2H 2026.","Initial data from Phase 1 cema-cel CLL trial expected by YE 2024; ALLO-329 IND planned Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":22000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247225,"accession_number":"0001737287-24-000019","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q4 net loss $85.8M, cash $448.7M; ALPHA3 trial to start mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $85.8M ($0.51/share); full-year net loss $327.3M ($2.09/share).","Cash, cash equivalents & investments $448.7M as of Dec 31, 2023; cash runway into 2026 reaffirmed.","2024 GAAP op. expenses ~$280M; expected cash burn ~$190M; non-cash comp ~$60M.","Pivotal cema-cel ALPHA3 1L LBCL trial enrollment begins mid-2024; randomized 230 MRD+ patients.","ALLO-329 (CD19 Dagger) for autoimmune disease to enter Phase 1 in early 2025; Arbor Biotechnologies licensing deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247224,"accession_number":"0001193125-24-038107","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Allogene restates 2020-2022 financials; material weakness in ICFR identified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee determined 2020-2022 annual and 2021-2023 quarterly reports should no longer be relied upon.","Error: equity method investment in Allogene Overland (49% stake) initially recorded at zero; should be fair value.","Restatement will record non-cash adjustments for seed preferred shares fair value and share of JV losses.","Management and EY concluded internal control over financial reporting was ineffective; material weakness identified.","Company targets filing restated 2022 10-K by March 14, 2024; no impact on cash or cash equivalents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247223,"accession_number":"0001737287-24-000003","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Allogene amends Notch collaboration, retains exclusive rights to one CAR target, gives up others","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Relinquished exclusive rights to all original CAR targets except one; option limited to one additional target.","If Notch out-licenses Released Targets, Allogene receives percentage of upfront/milestone payments up to a cap and low single-digit royalties.","Allogene made ~$22.7M total equity investments in Notch ($5M seed, $15.9M Series A, $1.8M common) and holds ~23% voting interest.","Amended Agreement includes anti-dilution protections for Allogene's stake in Notch for certain pre-IPO equity financings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247222,"accession_number":"0001193125-24-002888","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","8.01","2.05"],"status":"ready","headline":"Allogene to start pivotal ALPHA3 trial in 1L LBCL; cuts 22% staff, partners with Foresight","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~22% with estimated $5.0M-$5.5M in severance charges, mostly in Q1 2024.","Strategic collaboration with Foresight Diagnostics to develop MRD assay; Allogene to fund ~$26M.","Plans to initiate pivotal Phase 2 ALPHA3 trial mid-2024 for cema-cel in 1L LBCL, targeting MRD+ patients (n~230).","Deprioritizing 3L trials ALPHA2 and EXPAND; expects CD19 CAR T 2L/3L market to diminish."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264657,"accession_number":"0001737287-23-000096","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene gets FDA Fast Track for ALLO-647; safety data from 87 patients at ASH","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for ALLO-647 in adult patients with r/r LBCL.","Safety review of 87 Phase 1 patients: no unexpected safety concerns, no GvHD or Grade ≥3 ICANS.","33 CAR T-naïve LBCL patients had 42% CR rate, median DOR 23.1 months.","EXPAND trial (N=70 r/r LBCL) enrolling in US/EU to support licensure of ALLO-647.","Grade ≥3 cytopenias decreased over time; rates consistent with autologous CAR T therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264656,"accession_number":"0001737287-23-000089","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q3 net loss $61.3M; cash $497.7M; ALPHA2 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $61.3M ($0.37/sh) for Q3 2023; R&D expense $46.0M, G&A $17.0M.","Cash, equivalents and investments $497.7M as of Sept 30, 2023; runway into 2H 2025.","2023 guidance: cash use ~$230M; GAAP op. expense ~$340M incl. ~$80M stock comp.","ALPHA2 Phase 2 trial for ALLO-501A in LBCL enrolling; completion expected 1H 2024, data by end 2024.","New CFO Geoffrey Parker and General Counsel Earl Douglas appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":139000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264654,"accession_number":"0001737287-23-000083","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K/A","filed_at":"2023-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene appoints Geoffrey Parker as CFO with $490K salary and equity grants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoffrey Parker appointed EVP, CFO, Principal Financial and Accounting Officer effective Oct 16, 2023.","Replaces David Chang and Jack Chen as interim principal financial and accounting officers.","Prior roles: COO/CFO of Tricida, CFO of Anacor (acquired by Pfizer for $5.2B), MD at Goldman Sachs.","Compensation: $490K base salary, 45% target bonus, stock option for 950K shares, RSU for 400K shares.","Performance RSU of 390K shares vests upon $18.00 share price or first FDA product approval by 2026/2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264655,"accession_number":"0001737287-23-000079","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene appoints Geoffrey Parker as CFO effective Oct 16, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoffrey Parker named EVP, CFO, Principal Financial & Accounting Officer, effective Oct 16, 2023.","Previously COO/CFO at Tricida, CFO at Anacor (sold to Pfizer for $5.2B), MD at Goldman Sachs.","Receives $490k base salary, 45% target bonus pro-rated for 2023, option for 950k shares, 400k RSUs.","Also eligible for performance RSUs of 390k shares tied to $18 stock price or first FDA approval by 2028.","Severance under CIC Plan: 18 months salary on change-in-control termination; 12 months on involuntary termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281888,"accession_number":"0001737287-23-000074","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q2 2023 net loss of $78.0M; cash extends into 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $544.5M as of June 30, 2023; raised $87.9M via ATM in Q2.","Net loss $78.0M ($0.53/share) including $16.6M non-cash stock-based comp.","ALLO-501A Phase 2 ALPHA2 enrollment expected to complete 1H 2024; data readout by year-end 2024.","Long-term data from ALPHA/ALPHA2 trials showed complete response rates similar to approved autologous CAR T.","Cash runway now projected into 2H 2025; 2023 operating expense guidance ~$340M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":96000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300896,"accession_number":"0001737287-23-000067","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene reports updated Phase 1 data for ALLO-501/501A in r/r LBCL with 58% ORR and 42% CR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 33 CAR T-naïve patients, ORR 58%, CR 42%; 30% maintained CR at 6 months across all patients.","Phase 2 regimen (12 patients): ORR 67%, CR 58%; median duration of response 23.1 months.","No Grade ≥3 CRS, no ICANS or GvHD; cytopenia and infections manageable, comparable to autologous CAR T.","Company expects to complete enrollment of potentially pivotal Phase 2 ALPHA2 trial in 1H2024; plans to open sites in Europe, Canada, Australia in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300895,"accession_number":"0001737287-23-000063","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allogene Therapeutics shareholders elect four Class II directors, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deborah Messemer, Vicki Sato, Todd Sisitsky, and Owen Witte elected as Class II directors to serve until 2026.","Advisory vote on named executive officer compensation passed with 73,082,912 for, 31,751,974 against, 1,939,920 abstentions.","Ratification of Ernst & Young as independent auditor for FY2023 passed with 120,675,447 for, 36,870 against, 9,115 abstentions.","Broker non-votes of 13,946,626 on director election and say-on-pay; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300894,"accession_number":"0001737287-23-000060","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Eric Schmidt resigns effective August 2, 2023; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Schmidt, Ph.D., CFO, principal financial and accounting officer, resigned effective August 2, 2023.","Resignation voluntary to spend more time with family.","Company has initiated a search for a new CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300893,"accession_number":"0001737287-23-000056","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene reports 67% ORR and 58% CR in Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in r/r LBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["67% ORR and 58% CR in CAR T-naive r/r LBCL patients (n=12) treated with Phase 2 regimen at ASCO.","5 of 7 complete responders maintained CR at 6 months; median DOR 23.1 months; 3 patients in remission >24 months, longest >31 months.","No Grade 3+ CRS, ICANS, or GvHD; cytopenias and infections manageable; safety comparable to autologous CAR T.","Pivotal Phase 2 ALPHA2 trial of ALLO-501A enrolling; expected enrollment completion in first half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300892,"accession_number":"0001737287-23-000051","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q1 net loss $98.7M, cash $514M; clinical progress in ALLO-501A and ALLO-316","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $98.7M ($0.68/share); R&D $80.2M, G&A $18.9M; cash $514M as of March 31, 2023.","Phase 2 ALPHA2 trial enrollment ongoing for ALLO-501A in R/R large B cell lymphoma; expects enrollment completion 1H 2024.","Initiated EXPAND trial to support licensure of ALLO-647; randomized ~70 patients to FCA90 vs FC alone before ALLO-501A.","Interim Phase 1 data on ALLO-316 in RCC: 3 of 10 CD70+ patients achieved partial response; disease control rate 100% in CD70+ subset.","Appointed Timothy Moore as Chief Technical Officer; fiscal 2023 guidance: cash burn ~$230M, GAAP OpEx ~$340M, runway into Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":52000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300891,"accession_number":"0001737287-23-000028","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene CTO Alison Moore resigns; Tim Moore appointed as replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alison Moore resigns as Chief Technical Officer effective April 28, 2023 to pursue other opportunities.","Board appoints Tim Moore as CTO effective April 24, 2023; he will also provide transitional consulting.","No further details on reasons for departure or consulting terms were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320784,"accession_number":"0001737287-23-000023","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Allogene Therapeutics has no cash deposits or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms zero exposure to SVB amid its closure and industry uncertainty.","No cash or securities held at SVB; no financial impact from the bank's collapse.","Disclosure aims to address investor concerns about counterparty risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320783,"accession_number":"0001737287-23-000017","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q4 2022 net loss $94.8M, cash $576.5M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $94.8M ($0.66/share); full year net loss $332.6M ($2.32/share).","Cash, cash equivalents and investments $576.5M as of Dec 31, 2022; expects 2023 cash burn ~$250M, runway into 2025.","Initiated ALPHA2 Phase 2 trial of ALLO-501A in R/R LBCL; enrollment expected to complete 1H 2024.","Phase 1 data: ALLO-501A single dose FCA90 showed 67% ORR, 58% CR rate, median DoR 23.1 months.","UNIVERSAL trial of ALLO-715 in R/R MM: 67% ORR, 42% VGPR+ rate, median DoR 9.2 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":243000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320782,"accession_number":"0001737287-23-000003","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene Therapeutics EVP of R&D Rafael Amado resigns effective Dec 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rafael G. Amado, Executive Vice President of Research and Development, resigned.","Effective date of resignation: December 30, 2022.","Resignation is to pursue another opportunity; no replacement named.","Departure of top R&D executive may impact pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338916,"accession_number":"0001737287-22-000089","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene releases Phase 1 data across CAR T programs; initiates Phase 2 ALPHA2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single Dose FCA90 in LBCL achieved 67% ORR, 58% CR; 50% in CR at 6 and 12 months. No Grade 3+ CRS or neurotoxicity.","ALLO-715 in MM expansion (FCA60): 67% ORR, 42% VGPR+ (all MRD-negative), median DOR 9.2 months, longest 24 months.","ALLO-316 in RCC CD70+ patients (n=9): 100% disease control, 33% partial responses; generally manageable safety.","Phase 2 ALPHA2 trial enrolling ~100 LBCL patients; planning pivotal Phase 2 for ALLO-715 and evaluating ALLO-316 expansion.","Research update: Dagger technology aims to delay AlloCAR T rejection; ALLO-605 trial paused for manufacturing review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338915,"accession_number":"0001737287-22-000081","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q3 net loss of $83.1M; initiates first allogeneic CAR T Phase 2 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $83.1M ($0.58/share); R&D expenses $63.6M; G&A $18.9M.","Cash & investments $637M at Sep 30; 2022 cash burn guidance <$250M.","Initiated ALPHA2 Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma.","R&D Showcase on Nov 29, 2022 to feature updated CD19 and BCMA data.","FY 2022 GAAP operating expenses slightly below prior $360M-$390M guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":196000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338914,"accession_number":"0001737287-22-000074","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene initiates Phase 2 ALPHA2 trial of ALLO-501A in r/r LBCL; plans EXPAND trial for ALLO-647","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALPHA2 trial will enroll ~100 r/r LBCL patients with single 120M CAR+ cell dose; primary endpoint ORR.","EXPAND trial (~70 patients) randomized to assess ALLO-647 contribution to lymphodepletion regimen.","FDA cleared manufacturing from CF1 using non-Alloy process; Alloy process being implemented at CF1.","Company plans to seek FDA approval based on ALPHA2 and EXPAND trials assuming favorable outcomes.","CD19 program update, including longer-term Phase 1 follow-up with Alloy process, expected end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356291,"accession_number":"0001737287-22-000072","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-09-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Servier discontinues CD19 development; Allogene may exercise ex-US license at added cost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Servier sent discontinuation notice for CD19 products (UCART19, ALLO-501, ALLO-501A) per Servier Agreement.","Allogene can elect ex-US license; if exercised, milestone payments for ALLO-501A increase by €46M aggregate.","Allogene's right to recover 40% of development costs from Servier would cease upon exercise of ex-US option.","Servier requested Allogene exercise option within limited timeframe; Cellectis challenges sublicense rights, adding legal risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356290,"accession_number":"0001737287-22-000065","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene expects FDA clearance for first allogeneic CAR T pivotal trial; Q2 net loss $74.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA clearance expected in coming weeks for Phase 2 pivotal trial of ALLO-501A in LBCL; would be first allogeneic CAR T pivotal trial.","Ended Q2 2022 with $686M cash, cash equivalents and investments; net loss $74.8M ($0.52 per share).","Full year GAAP OpEx guided to low end of $360M-$390M; cash burn ~$250M for 2022.","CF1 manufacturing facility operational; projected capacity ~20,000 doses/year; earned LEED Gold designation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":147000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356289,"accession_number":"0001737287-22-000049","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene appoints Stephen Mayo, Ph.D. to Board; board expands to 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 11 to 12; Mayo appointed as Class III director, term expires at 2024 annual meeting.","Annual cash retainer of $40,000 for board service under non-employee director compensation policy.","Initial equity grants: option and RSU each with $425,000 grant date value, vesting over 3 years and 3 annual installments.","Director eligible for annual automatic option/RSU grants with $425,000 value on each annual meeting date.","Equity grants accelerate fully upon change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374668,"accession_number":"0001737287-22-000039","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allogene shareholders elect directors, approve authorized share increase to 400M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four Class I directors elected: Elizabeth Barrett, Arie Belldegrun, David Bonderman, David Chang.","Advisory vote on executive compensation passed: 103,325,400 for, 7,596,094 against.","Authorized common shares increased from 200M to 400M; amendment filed June 16, 2022.","Stock option exchange program approved: 77,394,629 for, 33,536,201 against.","Ernst & Young ratified as auditor for FY2022: 125,514,754 for, 49,928 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374667,"accession_number":"0001737287-22-000033","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q1 net loss $79.9M, cash $733M; plans pivotal ALLO-501A trial mid-2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $79.9M ($0.56/sh); R&D $60.2M, G&A $19.9M; cash $733.1M at March 31, 2022.","Pivotal Phase 2 ALPHA2 trial of ALLO-501A in R/R large B cell lymphoma to start mid-2022 using CF1 product.","FDA granted Orphan Drug Designation for ALLO-605 (TurboCAR) for multiple myeloma; Fast Track for ALLO-316 for RCC.","Full-year 2022 GAAP OpEx guided at $360-390M, including $90-100M stock-based compensation.","Cell Forge 1 operational; projected annual capacity of ~20,000 AlloCAR T doses at scale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":61000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-04T23:59:59+00:00|374667"}